OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

Proteogenomics Research

Proteogenomics Research – On the Frontier of Precision Medicine

Learn about cancer genomics, how it is being integrated with proteomics (termed proteogenomics), and how proteogenomics is anticipated to improve precision medicine.

CPTAC Biospecimen Collection Solicitation

A funding opportunity in support of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) seeks to prospectively procure tumor samples, collected for proteomics investigation. The scope of work under this Statement of Work encompasses the activities needed to...


Opportunities for Cancer-relevant Innovative Technologies with Transformative Potential

The National Cancer Institute (NCI) is seeking input from the community on identifying priorities with regards to supporting innovative technology development for cancer-relevant research. While the NCI provides support for technology development through a variety of mechanisms, it is important...


NCI Requests Targets for Monoclonal Antibody Production and Characterization

In an effort to provide well-characterized monoclonal antibodies to the scientific community, NCI's Antibody Characterization Program requests cancer-related protein targets for affinity production and distribution.

Submissions...


CPTAC-EDRN Joint Session
EDRN-CPTAC Joint Session at the 9th US-HUPO Annual Conference, Baltimore MD  

CPTAC Prospective Biospecimen Collection Solicitation

A new funding opportunity in support of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) seeks to prospectively procure tumor samples, collected for proteomics investigation.


NCI expands collaborative partnerships in proteomics research and antibody production/characterization
MOU Extends CPTAC Proteomics Standardized Workflows within an Active Clinical Research Setting

Innovative Molecular Analysis Technologies Program Funding Opportunities

The NCI is very pleased to announce that the Innovative Molecular Analysis Technologies (IMAT) program funding opportunity announcements have been posted for calendar year (CY) 2013. Please visit this website for more information on...


NIH Seeks Input on Prioritizing Renewable Affinity Reagents

The National Institutes of Health (NIH) is seeking community input on a priority list for renewable affinity reagents for human transcription factors. For more information or to provide input, please visit, ...


Contract Funding Opportunities Available for Innovative SBIR Development

Does your small business need early-stage financing to take its cancer research to the next level? 


CPTAC Launches Proteomics Data Portal

The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the launch of the CPTAC Data Portal. The Data Portal hosts all the data that is currently being produced by the consortium with additional historic data from CPTAC 1. The total amount of hosted data...


Pages